Farmácia/Notícias da Indústria

Análise final de sobrevida: Apalutamida em pacientes com câncer de próstata metastático sensível à castração

4 Mai, 2021 | 09:32h

Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study – Journal of Clinical Oncology

Comentário no Twitter

Just in JCO @ASCO 👉Glad to share final OS data from TITAN trial after ~4 yrs of follow up: unprecedented OS benefit with APALUTAMIDE/ APA after adjusting for crossover from placebo👉48% reduction in risk of death with APA, HR=0.52 👇https://t.co/9ZCoXsTE6x @oncoalert @urotoday pic.twitter.com/FNBFA84DxY

— Neeraj Agarwal (@neerajaiims) April 29, 2021

Ensaio RECOVERY: Em pacientes com COVID-19 hospitalizados com hipóxia e inflamação sistêmica (proteína C reativa ≥ 75 mg/L), tocilizumabe melhorou a sobrevida e outros desfechos clínicos

3 Mai, 2021 | 10:53h

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial – The Lancet

Comentário: Tocilizumab in COVID-19: some clarity amid controversy – The Lancet

M-A: Tocilizumabe reduz a necessidade de ventilação mecânica em pacientes com COVID-19, mas os estudos randomizados incluídos na análise mostraram que não há efeito significativo sobre o risco de mortalidade ou de eventos adversos

3 Mai, 2021 | 10:51h

Efficacy and safety of tocilizumab in COVID-19 patients: A living systematic Review and meta-analysis: first update – Clinical Microbiology and Infection

Série de casos de 12 pacientes com trombose do seio venoso cerebral com trombocitopenia após vacinação com Ad26.COV2.S – Todas são mulheres com menos de 60 anos apresentando sintomas entre 6 e 15 dias depois da vacinação

3 Mai, 2021 | 10:50h

US Case Reports of Cerebral Venous Sinus Thrombosis With Thrombocytopenia After Ad26.COV2.S Vaccination, March 2 to April 21, 2021 – JAMA

Editorial: Assessing a Rare and Serious Adverse Event Following Administration of the Ad26.COV2.S Vaccine – JAMA

Ver também: Safety Monitoring of the Janssen (Johnson & Johnson) COVID-19 Vaccine — United States, March–April 2021 – Centers for Disease Control and Prevention E Updated Recommendations from the Advisory Committee on Immunization Practices for Use of the Janssen (Johnson & Johnson) COVID-19 Vaccine After Reports of Thrombosis with Thrombocytopenia Syndrome Among Vaccine Recipients — United States, April 2021 – Centers for Disease Control and Prevention

Relacionado: AHA/ASA Guidance: Diagnosis and Management of Cerebral Venous Sinus Thrombosis with Vaccine-Induced Thrombotic Thrombocytopenia – “No heparin products in any dose should be given.”

M-A: Redução farmacológica da pressão arterial nas prevenções primária e secundária de doença cardiovascular – “uma redução de 5 mmHg na PA sistólica reduziu o risco de eventos maiores de DC em cerca de 10%, a despeito de diagnósticos prévios de DC ou mesmo em pacientes com valores de PA normais ou de normais a altos”

3 Mai, 2021 | 10:35h

Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis – The Lancet

Comentários: Many more people could benefit from blood pressure-lowering medication – The Lancet E Decisions about antihypertensive treatment should focus on reducing cardiovascular risk – The Lancet

Diretriz clínica da ACG: Diagnóstico e tratamento da lesão hepática idiossincrática induzida por drogas – As classes de agentes mais comuns são antimicrobianos, suplementos naturais e dietéticos e tratamentos anticâncer

3 Mai, 2021 | 10:32h

ACG Clinical Guideline: Diagnosis and Management of Idiosyncratic Drug-Induced Liver Injury – The American Journal of Gastroenterology

ECR: Ácido tranexâmico na prevenção de perda sanguínea após parto cesariano – Embora o uso de AT tenha resultado em redução na incidência da perda sanguínea estimada, a relevância clínica dos achados foi pequena.

30 Abr, 2021 | 09:17h

Tranexamic Acid for the Prevention of Blood Loss after Cesarean Delivery – New England Journal of Medicine

Comentários no Twitter

Another typically "positive" trial for TXA.

"the mean between-group difference was approximately 100 ml …. the clinical relevance of this narrow difference is questionable"
– No difference in RBC transfusions.
– 0.4% vs 0.1% VTE at 3 mos.

🤷‍♂️https://t.co/KX4OZUyZVK

— Ryan Radecki, MD MS (@emlitofnote) April 28, 2021

NEJM-Prevention of Blood Loss after Cesarean Delivery | tranexamic acid ➡️ significantly lower incidence of EBL greater than 1000 ml or RBC transfusion by day 2 than placebo, but did not result in a ⬇️ incidence of hemorrhage-related secondary outcomes https://t.co/ydF5HgHM0N

— Skeptical Scalpel (@Skepticscalpel) April 28, 2021

M-A: Prescrição tardia de antibióticos para infecções do trato respiratório é uma estratégia segura e eficaz para a maioria dos pacientes

30 Abr, 2021 | 09:15h

Delayed antibiotic prescribing for respiratory tract infections: individual patient data meta-analysis – The BMJ

Comentário: Delayed Antibiotic Prescribing Safe for Respiratory Tract Infection – HealthDay

Diretriz da AHA: Prevenção da endocardite infecciosa por Streptococcus do grupo viridans – Antibioticoprofilaxia para procedimentos dentais invasivos é indicada somente para pacientes de alto risco com as seguintes condições: prótese cardíaca valvar, endocardite infecciosa prévia, doença cardíaca congênita ou transplante cardíaco prévio.

30 Abr, 2021 | 09:11h

Prevention of Viridans Group Streptococcal Infective Endocarditis: A Scientific Statement From the American Heart Association

Comunicado de Imprensa: Good dental health may help prevent heart infection from mouth bacteria – American Heart Association

Principais Itens a Saber: Prevention of Viridans Group Streptococcal Infective Endocarditis – American Heart Association

Slide set: Prevention of Viridans Group Streptococcal Infective Endocarditis

Comentário: Commentary for Prevention of Viridans Group Streptococcal Infective Endocarditis – American Heart Association

Comentário no Twitter (fio – clique para saber mais)

#ScholarlySunday

In 2007, antibiotic prophylaxis to prevent VGS IE was scaled back.

“There was no convincing evidence that VGS IE frequency, morbidity, or mortality has increased since 2007.”

Thanks Drs. @LBaddour1, Daniel DeSimone and Walter Wilsonhttps://t.co/r9It8c3IwA pic.twitter.com/EO3gcKZAzG

— Mayo Clinic Infectious Diseases (@MayoClinicINFD) April 18, 2021

Estudo de coorte: Uso concomitante de drogas-Z (zolpidem, zopiclona, zaleplona) e opioides aumenta sobremaneira o risco de overdose

30 Abr, 2021 | 09:08h

The Risk of Overdose With Concomitant Use of Z-Drugs and Prescription Opioids: A Population-Based Cohort Study – American Journal of Psychiatry (link para o resumo – $ para o texto completo)

Comentário: Co-prescribing Opioids, Z-Drugs May Increase Risk of Overdose – Psychiatric News Alert